ACE and metabolic dysfunction-associated steatotic liver disease: A recent cross-sectional study also showed that CKD-NAFLD patients taking angiotensin-converting enzyme inhibitors (ACE-I) or ARBs had less liver stiffness than patients not taking any medication [34].